ID   MYO1G_HUMAN             Reviewed;        1018 AA.
AC   B0I1T2; Q8TEI9; Q8TES2; Q96BE2; Q96RI5; Q96RI6;
DT   10-JUN-2008, integrated into UniProtKB/Swiss-Prot.
DT   11-JAN-2011, sequence version 2.
DT   28-JUN-2023, entry version 117.
DE   RecName: Full=Unconventional myosin-Ig;
DE   Contains:
DE     RecName: Full=Minor histocompatibility antigen HA-2 {ECO:0000303|PubMed:11544309};
DE              Short=mHag HA-2;
GN   Name=MYO1G; Synonyms=HA2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), NUCLEOTIDE SEQUENCE
RP   [LARGE SCALE MRNA] OF 193-1018 (ISOFORM 3), AND VARIANT THR-489.
RC   TISSUE=Spleen;
RA   Jikuya H., Takano J., Nomura N., Kikuno R., Nagase T., Ohara O.;
RT   "The nucleotide sequence of a long cDNA clone isolated from human spleen.";
RL   Submitted (JAN-2002) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANTS THR-489
RP   AND ARG-861.
RC   TISSUE=Spleen;
RA   Yamakawa H., Kikuno R.F., Nagase T., Ohara O.;
RT   "Multiplex amplification and cloning of 5'-ends of cDNA by ligase-free
RT   recombination: preparation of full-length cDNA clones encoding motor
RT   proteins.";
RL   Submitted (JAN-2007) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K.,
RA   Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A.,
RA   Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H.,
RA   Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A.,
RA   Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P.,
RA   Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M.,
RA   Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S.,
RA   Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R.,
RA   Strowmatt C., Latreille P., Miller N., Johnson D., Murray J.,
RA   Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W.,
RA   Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A.,
RA   Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E.,
RA   Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A.,
RA   Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A.,
RA   Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R.,
RA   McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H.,
RA   Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 33-665 (ISOFORM 4), IDENTIFICATION AS THE
RP   MINOR HISTOCOMPATIBILITY ANTIGEN HA-2, VARIANTS HA-2M MET-49 AND THR-489,
RP   CHARACTERIZATION OF VARIANT HA-2M MET-49, AND TISSUE SPECIFICITY.
RX   PubMed=11544309; DOI=10.4049/jimmunol.167.6.3223;
RA   Pierce R.A., Field E.D., Mutis T., Golovina T.N., Von Kap-Herr C.,
RA   Wilke M., Pool J., Shabanowitz J., Pettenati M.J., Eisenlohr L.C.,
RA   Hunt D.F., Goulmy E., Engelhard V.H.;
RT   "The HA-2 minor histocompatibility antigen is derived from a diallelic gene
RT   encoding a novel human class I myosin protein.";
RL   J. Immunol. 167:3223-3230(2001).
RN   [5]
RP   PROTEIN SEQUENCE OF 41-49 (ISOFORM 1).
RX   PubMed=7539551; DOI=10.1126/science.7539551;
RA   den Haan J.M.M., Sherman N.E., Blokland E., Huczko E., Koning F.,
RA   Drijfhout J.W., Skipper J., Shabanowitz J., Hunt D.F., Engelhard V.H.,
RA   Goulmy E.;
RT   "Identification of a graft versus host disease-associated human minor
RT   histocompatibility antigen.";
RL   Science 268:1476-1480(1995).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 723-1018 (ISOFORM 1), AND VARIANT
RP   ARG-861.
RC   TISSUE=B-cell;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   SUBCELLULAR LOCATION.
RX   PubMed=19968988; DOI=10.1016/j.febslet.2009.11.096;
RA   Olety B., Walte M., Honnert U., Schillers H., Bahler M.;
RT   "Myosin 1G (Myo1G) is a haematopoietic specific myosin that localises to
RT   the plasma membrane and regulates cell elasticity.";
RL   FEBS Lett. 584:493-499(2010).
RN   [8]
RP   SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND MUTAGENESIS OF LYS-815;
RP   ARG-826; ARG-876; ARG-880; ARG-885; LYS-898; ARG-903; ARG-906; ARG-909;
RP   ARG-934; ARG-945; ARG-947 AND ARG-953.
RX   PubMed=20071333; DOI=10.1074/jbc.m109.086959;
RA   Patino-Lopez G., Aravind L., Dong X., Kruhlak M.J., Ostap E.M., Shaw S.;
RT   "Myosin 1G is an abundant class I myosin in lymphocytes whose localization
RT   at the plasma membrane depends on its ancient divergent pleckstrin homology
RT   (PH) domain (Myo1PH).";
RL   J. Biol. Chem. 285:8675-8686(2010).
RN   [9]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
CC   -!- FUNCTION: Unconventional myosin required during immune response for
CC       detection of rare antigen-presenting cells by regulating T-cell
CC       migration. Unconventional myosins are actin-based motor molecules with
CC       ATPase activity and serve in intracellular movements. Acts as a
CC       regulator of T-cell migration by generating membrane tension, enforcing
CC       cell-intrinsic meandering search, thereby enhancing detection of rare
CC       antigens during lymph-node surveillance, enabling pathogen eradication.
CC       Also required in B-cells, where it regulates different
CC       membrane/cytoskeleton-dependent processes. Involved in Fc-gamma
CC       receptor (Fc-gamma-R) phagocytosis. {ECO:0000250|UniProtKB:Q5SUA5}.
CC   -!- FUNCTION: [Minor histocompatibility antigen HA-2]: Constitutes the
CC       minor histocompatibility antigen HA-2. More generally, minor
CC       histocompatibility antigens (mHags) refer to immunogenic peptide which,
CC       when complexed with MHC, can generate an immune response after
CC       recognition by specific T-cells. The peptides are derived from
CC       polymorphic intracellular proteins, which are cleaved by normal
CC       pathways of antigen processing. The binding of these peptides to MHC
CC       class I or class II molecules and their expression on the cell surface
CC       can stimulate T-cell responses and thereby trigger graft rejection or
CC       graft-versus-host disease (GVHD) after hematopoietic stem cell
CC       transplantation from HLA-identical sibling donor. GVHD is a frequent
CC       complication after bone marrow transplantation (BMT), due to mismatch
CC       of minor histocompatibility antigen in HLA-matched sibling marrow
CC       transplants. HA-2 is restricted to MHC class I HLA-A*0201.
CC       {ECO:0000269|PubMed:11544309, ECO:0000305}.
CC   -!- SUBUNIT: Interacts with calmodulin; via its IQ motifs. {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:19968988,
CC       ECO:0000269|PubMed:20071333}; Peripheral membrane protein
CC       {ECO:0000269|PubMed:19968988, ECO:0000269|PubMed:20071333}. Cell
CC       projection, phagocytic cup {ECO:0000250|UniProtKB:Q5SUA5}.
CC       Note=Recruited to Fc-gamma receptor (Fc-gamma-R) phagocytic cup. In T-
CC       cells, transiently accumulates in discrete areas at the plasma membrane
CC       of migrating cells or when membranes are deformed (By similarity).
CC       Localization at the membrane is not highly dependent on
CC       phosphatidylinositol 4,5-bisphosphate levels. Released from the
CC       membrane in the presence of ATP. May be enriched in peripheral
CC       processes, such as microvilli or ruffles.
CC       {ECO:0000250|UniProtKB:Q5SUA5, ECO:0000269|PubMed:20071333}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=B0I1T2-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=B0I1T2-2; Sequence=VSP_034208, VSP_034209;
CC       Name=3;
CC         IsoId=B0I1T2-3; Sequence=VSP_034210;
CC       Name=4;
CC         IsoId=B0I1T2-4; Sequence=VSP_034211, VSP_034212;
CC   -!- TISSUE SPECIFICITY: Specifically expressed in hematopoietic cells.
CC       {ECO:0000269|PubMed:11544309, ECO:0000269|PubMed:20071333}.
CC   -!- DOMAIN: The myosin tail domain mediates binding to
CC       phosphatidylinositol-3,4-bisphosphate (PtdIns(3,4)P2),
CC       phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P2) and
CC       phosphatidylinositol-3,4,5-trisphosphate (PtdIns(3,4,5)P3) and binds to
CC       membranous compartments. It is required for recruitment to Fc-gamma
CC       receptor (Fc-gamma-R) phagocytic cups. {ECO:0000250|UniProtKB:Q5SUA5}.
CC   -!- SIMILARITY: Belongs to the TRAFAC class myosin-kinesin ATPase
CC       superfamily. Myosin family. {ECO:0000305}.
CC   -!- CAUTION: Represents an unconventional myosin. This protein should not
CC       be confused with the conventional myosin-1 (MYH1). {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAB84876.1; Type=Erroneous translation; Note=Wrong choice of CDS.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK074050; BAB84876.1; ALT_SEQ; mRNA.
DR   EMBL; AK074135; BAB84961.1; -; mRNA.
DR   EMBL; AB290179; BAG06733.1; -; mRNA.
DR   EMBL; AC004847; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AF380932; AAK58092.1; -; mRNA.
DR   EMBL; AF380933; AAK58093.1; -; mRNA.
DR   EMBL; BC015693; AAH15693.2; -; mRNA.
DR   CCDS; CCDS34629.1; -. [B0I1T2-1]
DR   RefSeq; NP_149043.2; NM_033054.2. [B0I1T2-1]
DR   AlphaFoldDB; B0I1T2; -.
DR   SMR; B0I1T2; -.
DR   BioGRID; 122031; 12.
DR   IntAct; B0I1T2; 10.
DR   MINT; B0I1T2; -.
DR   STRING; 9606.ENSP00000258787; -.
DR   GlyCosmos; B0I1T2; 1 site, 1 glycan.
DR   GlyGen; B0I1T2; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; B0I1T2; -.
DR   MetOSite; B0I1T2; -.
DR   PhosphoSitePlus; B0I1T2; -.
DR   SwissPalm; B0I1T2; -.
DR   BioMuta; MYO1G; -.
DR   CPTAC; CPTAC-1620; -.
DR   EPD; B0I1T2; -.
DR   jPOST; B0I1T2; -.
DR   MassIVE; B0I1T2; -.
DR   MaxQB; B0I1T2; -.
DR   PaxDb; B0I1T2; -.
DR   PeptideAtlas; B0I1T2; -.
DR   ProteomicsDB; 2548; -. [B0I1T2-1]
DR   ProteomicsDB; 2549; -. [B0I1T2-2]
DR   ProteomicsDB; 2550; -. [B0I1T2-3]
DR   ProteomicsDB; 2551; -. [B0I1T2-4]
DR   Antibodypedia; 13492; 87 antibodies from 15 providers.
DR   DNASU; 64005; -.
DR   Ensembl; ENST00000258787.12; ENSP00000258787.7; ENSG00000136286.16. [B0I1T2-1]
DR   GeneID; 64005; -.
DR   KEGG; hsa:64005; -.
DR   MANE-Select; ENST00000258787.12; ENSP00000258787.7; NM_033054.3; NP_149043.2.
DR   UCSC; uc003tmh.3; human. [B0I1T2-1]
DR   AGR; HGNC:13880; -.
DR   CTD; 64005; -.
DR   DisGeNET; 64005; -.
DR   GeneCards; MYO1G; -.
DR   HGNC; HGNC:13880; MYO1G.
DR   HPA; ENSG00000136286; Tissue enhanced (bone marrow, lymphoid tissue).
DR   MIM; 600642; gene.
DR   neXtProt; NX_B0I1T2; -.
DR   OpenTargets; ENSG00000136286; -.
DR   VEuPathDB; HostDB:ENSG00000136286; -.
DR   eggNOG; KOG0160; Eukaryota.
DR   eggNOG; KOG0164; Eukaryota.
DR   GeneTree; ENSGT00940000158053; -.
DR   HOGENOM; CLU_000192_7_7_1; -.
DR   InParanoid; B0I1T2; -.
DR   OMA; MRAYKTY; -.
DR   OrthoDB; 1094820at2759; -.
DR   PhylomeDB; B0I1T2; -.
DR   TreeFam; TF312960; -.
DR   PathwayCommons; B0I1T2; -.
DR   SignaLink; B0I1T2; -.
DR   BioGRID-ORCS; 64005; 31 hits in 1149 CRISPR screens.
DR   ChiTaRS; MYO1G; human.
DR   GenomeRNAi; 64005; -.
DR   Pharos; B0I1T2; Tbio.
DR   PRO; PR:B0I1T2; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   RNAct; B0I1T2; protein.
DR   Bgee; ENSG00000136286; Expressed in granulocyte and 156 other tissues.
DR   ExpressionAtlas; B0I1T2; baseline and differential.
DR   Genevisible; B0I1T2; HS.
DR   GO; GO:0015629; C:actin cytoskeleton; IBA:GO_Central.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0030175; C:filopodium; IEA:Ensembl.
DR   GO; GO:0030027; C:lamellipodium; IEA:Ensembl.
DR   GO; GO:0031256; C:leading edge membrane; IEA:Ensembl.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0005902; C:microvillus; IEA:Ensembl.
DR   GO; GO:0016459; C:myosin complex; IEA:UniProtKB-KW.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0001891; C:phagocytic cup; ISS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:MGI.
DR   GO; GO:0031982; C:vesicle; IBA:GO_Central.
DR   GO; GO:0051015; F:actin filament binding; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005516; F:calmodulin binding; IEA:UniProtKB-KW.
DR   GO; GO:0003774; F:cytoskeletal motor activity; IEA:InterPro.
DR   GO; GO:0005547; F:phosphatidylinositol-3,4,5-trisphosphate binding; ISS:UniProtKB.
DR   GO; GO:0043325; F:phosphatidylinositol-3,4-bisphosphate binding; ISS:UniProtKB.
DR   GO; GO:0005546; F:phosphatidylinositol-4,5-bisphosphate binding; ISS:UniProtKB.
DR   GO; GO:0007015; P:actin filament organization; IBA:GO_Central.
DR   GO; GO:0071976; P:cell gliding; IEA:Ensembl.
DR   GO; GO:0031589; P:cell-substrate adhesion; IEA:Ensembl.
DR   GO; GO:0006887; P:exocytosis; IEA:Ensembl.
DR   GO; GO:0038096; P:Fc-gamma receptor signaling pathway involved in phagocytosis; ISS:UniProtKB.
DR   GO; GO:0120117; P:T cell meandering migration; IEA:Ensembl.
DR   GO; GO:0002456; P:T cell mediated immunity; ISS:UniProtKB.
DR   GO; GO:0072678; P:T cell migration; ISS:UniProtKB.
DR   GO; GO:0030050; P:vesicle transport along actin filament; IBA:GO_Central.
DR   CDD; cd01378; MYSc_Myo1; 1.
DR   Gene3D; 1.10.10.820; -; 1.
DR   Gene3D; 1.20.5.4820; -; 1.
DR   Gene3D; 1.20.58.530; -; 1.
DR   Gene3D; 3.40.850.10; Kinesin motor domain; 1.
DR   Gene3D; 1.20.120.720; Myosin VI head, motor domain, U50 subdomain; 1.
DR   InterPro; IPR036961; Kinesin_motor_dom_sf.
DR   InterPro; IPR001609; Myosin_head_motor_dom.
DR   InterPro; IPR010926; Myosin_TH1.
DR   InterPro; IPR036072; MYSc_Myo1.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   PANTHER; PTHR13140; MYOSIN; 1.
DR   PANTHER; PTHR13140:SF381; UNCONVENTIONAL MYOSIN-IG; 1.
DR   Pfam; PF00063; Myosin_head; 1.
DR   Pfam; PF06017; Myosin_TH1; 1.
DR   PRINTS; PR00193; MYOSINHEAVY.
DR   SMART; SM00242; MYSc; 1.
DR   SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1.
DR   PROSITE; PS51456; MYOSIN_MOTOR; 1.
DR   PROSITE; PS51757; TH1; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Actin-binding; Adaptive immunity; Alternative splicing;
KW   ATP-binding; Calmodulin-binding; Cell membrane; Cell projection;
KW   Direct protein sequencing; Immunity; Lipid-binding; Membrane;
KW   Motor protein; Myosin; Nucleotide-binding; Reference proteome.
FT   CHAIN           1..1018
FT                   /note="Unconventional myosin-Ig"
FT                   /id="PRO_0000340316"
FT   PEPTIDE         41..49
FT                   /note="Minor histocompatibility antigen HA-2"
FT                   /evidence="ECO:0000269|PubMed:7539551"
FT                   /id="PRO_0000340317"
FT   DOMAIN          9..707
FT                   /note="Myosin motor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00782"
FT   DOMAIN          710..739
FT                   /note="IQ"
FT   DOMAIN          824..1017
FT                   /note="TH1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01093"
FT   REGION          584..606
FT                   /note="Actin-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00782"
FT   BINDING         102..109
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         1
FT                   /note="N-acetylmethionine"
FT                   /evidence="ECO:0007744|PubMed:25944712"
FT   VAR_SEQ         207..230
FT                   /note="LLRGSEDKQLHELHLERNPAVYNF -> VSPEGKGRWKNGVGKGRAASWTSL
FT                   (in isoform 2)"
FT                   /evidence="ECO:0000303|Ref.1"
FT                   /id="VSP_034208"
FT   VAR_SEQ         231..1018
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|Ref.1"
FT                   /id="VSP_034209"
FT   VAR_SEQ         526..1018
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|Ref.1"
FT                   /id="VSP_034210"
FT   VAR_SEQ         652..722
FT                   /note="KMTCEYTWPNHLLGSDKAAVSALLEQHGLQGDVAFGHSKLFIRSPRTLVTLE
FT                   QSRARLIPIIVLLLQKAWR -> WHLTPITPWAIVPVWSPRGRSRGSPNSTSQTSIQAG
FT                   TSTLLASRHQNIWEDMCVSTCMWGHTGGNMGMRAV (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:11544309"
FT                   /id="VSP_034211"
FT   VAR_SEQ         723..1018
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:11544309"
FT                   /id="VSP_034212"
FT   VARIANT         49
FT                   /note="V -> M (in allele HA-2M; the HA-2V allele constitute
FT                   the HA-2 epitope while HA-2M is not recognized by HA-2
FT                   cytotoxic T lymphocytes; dbSNP:rs61739531)"
FT                   /evidence="ECO:0000269|PubMed:11544309"
FT                   /id="VAR_044013"
FT   VARIANT         489
FT                   /note="M -> T (in dbSNP:rs3735485)"
FT                   /evidence="ECO:0000269|PubMed:11544309, ECO:0000269|Ref.1,
FT                   ECO:0000269|Ref.2"
FT                   /id="VAR_044014"
FT   VARIANT         798
FT                   /note="R -> Q (in dbSNP:rs2107737)"
FT                   /id="VAR_050212"
FT   VARIANT         861
FT                   /note="Q -> R (in dbSNP:rs7792760)"
FT                   /evidence="ECO:0000269|PubMed:15489334, ECO:0000269|Ref.2"
FT                   /id="VAR_044015"
FT   MUTAGEN         815
FT                   /note="K->A: Reduced membrane association."
FT                   /evidence="ECO:0000269|PubMed:20071333"
FT   MUTAGEN         826
FT                   /note="R->A: Reduced membrane association."
FT                   /evidence="ECO:0000269|PubMed:20071333"
FT   MUTAGEN         876
FT                   /note="R->A: No effect on membrane localization."
FT                   /evidence="ECO:0000269|PubMed:20071333"
FT   MUTAGEN         880
FT                   /note="R->A: No effect on membrane localization."
FT                   /evidence="ECO:0000269|PubMed:20071333"
FT   MUTAGEN         883
FT                   /note="K->A: No effect on membrane localization; when
FT                   associated with R-885."
FT   MUTAGEN         885
FT                   /note="R->A: No effect on membrane localization; when
FT                   associated with K-883."
FT                   /evidence="ECO:0000269|PubMed:20071333"
FT   MUTAGEN         898
FT                   /note="K->A: Reduced membrane association."
FT                   /evidence="ECO:0000269|PubMed:20071333"
FT   MUTAGEN         903
FT                   /note="R->A: No effect on membrane localization; when
FT                   associated with R-906."
FT                   /evidence="ECO:0000269|PubMed:20071333"
FT   MUTAGEN         906
FT                   /note="R->A: No effect on membrane localization; when
FT                   associated with R-903."
FT                   /evidence="ECO:0000269|PubMed:20071333"
FT   MUTAGEN         909
FT                   /note="R->A: No effect on membrane localization."
FT                   /evidence="ECO:0000269|PubMed:20071333"
FT   MUTAGEN         934
FT                   /note="R->A: No effect on membrane localization."
FT                   /evidence="ECO:0000269|PubMed:20071333"
FT   MUTAGEN         945
FT                   /note="R->A: No effect on membrane localization."
FT                   /evidence="ECO:0000269|PubMed:20071333"
FT   MUTAGEN         947
FT                   /note="R->A: No effect on membrane localization."
FT                   /evidence="ECO:0000269|PubMed:20071333"
FT   MUTAGEN         953
FT                   /note="R->A: No effect on membrane localization."
FT                   /evidence="ECO:0000269|PubMed:20071333"
FT   CONFLICT        369
FT                   /note="N -> K (in Ref. 1; BAB84961)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        377
FT                   /note="P -> L (in Ref. 4; AAK58092/AAK58093)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   1018 AA;  116442 MW;  3EB4ACC3D99A86E9 CRC64;
     MEDEEGPEYG KPDFVLLDQV TMEDFMRNLQ LRFEKGRIYT YIGEVLVSVN PYQELPLYGP
     EAIARYQGRE LYERPPHLYA VANAAYKAMK HRSRDTCIVI SGESGAGKTE ASKHIMQYIA
     AVTNPSQRAE VERVKDVLLK STCVLEAFGN ARTNRNHNSS RFGKYMDINF DFKGDPIGGH
     IHSYLLEKSR VLKQHVGERN FHAFYQLLRG SEDKQLHELH LERNPAVYNF THQGAGLNMT
     VHSALDSDEQ SHQAVTEAMR VIGFSPEEVE SVHRILAAIL HLGNIEFVET EEGGLQKEGL
     AVAEEALVDH VAELTATPRD LVLRSLLART VASGGRELIE KGHTAAEASY ARDACAKAVY
     QRLFEWVVNR INSVMEPRGR DPRRDGKDTV IGVLDIYGFE VFPVNSFEQF CINYCNEKLQ
     QLFIQLILKQ EQEEYEREGI TWQSVEYFNN ATIVDLVERP HRGILAVLDE ACSSAGTITD
     RIFLQTLDMH HRHHLHYTSR QLCPTDKTME FGRDFRIKHY AGDVTYSVEG FIDKNRDFLF
     QDFKRLLYNS TDPTLRAMWP DGQQDITEVT KRPLTAGTLF KNSMVALVEN LASKEPFYVR
     CIKPNEDKVA GKLDENHCRH QVAYLGLLEN VRVRRAGFAS RQPYSRFLLR YKMTCEYTWP
     NHLLGSDKAA VSALLEQHGL QGDVAFGHSK LFIRSPRTLV TLEQSRARLI PIIVLLLQKA
     WRGTLARWRC RRLRAIYTIM RWFRRHKVRA HLAELQRRFQ AARQPPLYGR DLVWPLPPAV
     LQPFQDTCHA LFCRWRARQL VKNIPPSDMP QIKAKVAAMG ALQGLRQDWG CRRAWARDYL
     SSATDNPTAS SLFAQRLKTL QDKDGFGAVL FSSHVRKVNR FHKIRNRALL LTDQHLYKLD
     PDRQYRVMRA VPLEAVTGLS VTSGGDQLVV LHARGQDDLV VCLHRSRPPL DNRVGELVGV
     LAAHCQGEGR TLEVRVSDCI PLSHRGVRRL ISVEPRPEQP EPDFRCARGS FTLLWPSR
//
